Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024
November 12 2024 - 8:00AM
Business Wire
ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo
Acoustic Enhanced UltraSound (TAEUS®), today announced the
acceptance of a poster titled “Noninvasive assessment of steatotic
liver disease in individuals with class 2 and class 3 obesity” for
presentation at The Liver Meeting 2024, hosted by the American
Association for the Study of Liver Disease (AASLD), taking place
November 15-19 in San Diego.
“This presentation highlights the potential of our TAEUS
technology to obtain liver fat fraction measurements in patients
with body mass index (BMI) exceeding 35, where accurate and
reliable assessment of liver fat is challenging with existing
point-of-care solutions. In extreme cases, TAEUS was able to obtain
valid measurements of fat fraction in subjects with BMI exceeding
40, where the liver was more than 40mm below the skin surface. The
subjects in this presentation were derived from a larger study
comparing the performance of TAEUS to MRI measurements of fat
fraction in the liver,” stated Michael Thornton, Chief Technology
Officer of ENDRA. “We are pleased this abstract was accepted for
presentation at AASLD, the largest worldwide scientific conference
for liver diseases. We are committed to submitting additional
abstracts for presentation at medical and scientific meetings to
create further awareness of the unique capabilities of our TAEUS
technology in point-of-care applications.”
Publication Number: 2089 Title: Noninvasive
assessment of steatotic liver disease in individuals with class 2
and class 3 obesity Presenter: Michael Thornton
Session: Diagnostics and Biomarkers - MASH Date:
November 16, 2024 Time: 8:00am – 5:00pm Pacific Standard
Time
The poster will be available on the Research and Media section
of ENDRA's website after the conference ends.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to assess tissue fat content and monitor tissue ablation during
minimally invasive procedures, at the point of patient care. TAEUS®
is initially focused on the measurement of fat in the liver as a
means to assess and monitor steatotic liver disease (SLD) and
metabolic dysfunction-associated steatohepatitis (MASH), chronic
liver conditions that affect over two billion people globally, and
for which there are no practical diagnostic tools. For more
information, please visit www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on
historical fact are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of terms such as “approximate,” "anticipate," “attempt,” "believe,"
"could," "estimate," "expect," “forecast,” “future,” "goal,"
“hope,” "intend," "may," "plan," “possible,” “potential,”
“project,” "seek," "should," "will," “would,” or other comparable
terms (including the negative of any of the foregoing), although
some forward-looking statements are expressed differently. Examples
of forward-looking statements for ENDRA include, among others:
expectations with respect to FDA requirements regarding its
clinical trials and de novo submission for its TAEUS liver device;
estimates of the timing of future events and anticipated results of
its development efforts, including the timing of submission for and
receipt of required regulatory approvals and product launches and
sales; statements relating to future financial position and
projected costs and revenue; expectations concerning ENDRA's
business strategy; and statements regarding ENDRA’s ability to find
and maintain development partners. Forward-looking statements
involve inherent risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking
statements as a result of various factors including, among others:
the ability to raise additional capital in order to continue as a
going concern; the ability to obtain FDA and other regulatory
approvals necessary to sell ENDRA medical devices in certain
markets in a timely manner, or at all; the ability to develop a
commercially feasible technology and its dependence on third
parties to design and manufacture its products; ENDRA’s ability to
maintain compliance with Nasdaq listing standards; ENDRA’s
dependence on its senior management team; market acceptance of
ENDRA’s technology and the amount and nature of competition in its
industry; ENDRA’s ability to protect its intellectual property; and
the other risks and uncertainties described in the Risk Factors and
Management’s Discussion and Analysis of Financial Condition and
Results of Operations sections of the company’s most recent Annual
Report on Form 10-K and in subsequent Quarterly Reports on Form
10-Q filed with the Securities and Exchange Commission. You should
not rely upon forward-looking statements as predictions of future
events. The forward-looking statements made in this press release
speak only as of the date of issuance, and ENDRA assumes no
obligation to update any such forward-looking statements to reflect
actual results or changes in expectations, except as otherwise
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241112955229/en/
Company: Richard Jacroux Chief Financial Officer
investors@endrainc.com www.endrainc.com
Investor Relations: Yvonne Briggs Alliance Advisors IR
(310) 691-7100 ybriggs@allianceadvisors.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Oct 2024 to Nov 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Nov 2023 to Nov 2024